Azstarys is not currently approved or marketed in Canada for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The drug is approved in the United States by the Food and Drug Administration (FDA) for individuals aged 6 and older.
When might Azstarys be available in Canada?
The availability of Azstarys in Canada depends on Health Canada's approval process. Drug manufacturers must submit a New Drug Submission (NDS) to Health Canada, which reviews extensive data on the drug's safety, efficacy, and quality. There is no publicly available information at this time indicating that an NDS for Azstarys has been filed with Health Canada.
What is Azstarys used for?
Azstarys (lisdexamfetamine dimesylate and dexmethylphenidate) is a central nervous system (CNS) stimulant used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults [1]. It works by increasing levels of certain neurotransmitters in the brain.
How does Azstarys work?
Azstarys is a combination medication containing two stimulants: lisdexamfetamine dimesylate and dexmethylphenidate. Lisdexamfetamine is a prodrug that is converted in the body to dextroamphetamine. Dexmethylphenidate is the d-enantiomer of methylphenidate. Both amphetamine and methylphenidate increase the levels of dopamine and norepinephrine in the brain, which are thought to be deficient in individuals with ADHD. This action helps to improve focus, attention, and impulse control [1].
What are the key differences between Azstarys and other ADHD medications?
Azstarys is unique in that it is the first ADHD medication approved in the United States to contain two different stimulant medications. Lisdexamfetamine is a long-acting amphetamine-based stimulant, while dexmethylphenidate is a methylphenidate-based stimulant. This dual-component approach may offer a different pharmacokinetic profile and potentially a different therapeutic effect compared to single-stimulant medications.
What are the potential side effects of Azstarys?
Common side effects of Azstarys can include decreased appetite, insomnia, dry mouth, nausea, vomiting, anxiety, increased heart rate, and increased blood pressure [1]. Serious side effects can include cardiovascular problems, psychiatric disorders, and circulation problems in the extremities. Patients should discuss potential risks and benefits with their healthcare provider.
Where can I find more information on drug approvals and patents?
Information on drug approvals and patent expirations in various countries, including Canada, can be found on specialized databases. For instance, DrugPatentWatch.com tracks patent information and regulatory status for pharmaceuticals [2].